LYKALABS

Lyka Labs Share Price

 

 

Start SIP in LYKALABS

Start SIP

Performance

  • Low
  • ₹75
  • High
  • ₹77
  • 52 Week Low
  • ₹72
  • 52 Week High
  • ₹167
  • Open Price₹77
  • Previous Close₹76
  • Volume12,325

Investment Returns

  • Over 1 Month -6.89%
  • Over 3 Month -24.35%
  • Over 6 Month -33.9%
  • Over 1 Year -49.88%

Smart Investing Starts Here Start SIP with Lyka Labs for Steady Growth!

Invest Now

Lyka Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 130.4
  • PEG Ratio
  • -3.2
  • Market Cap Cr
  • 268
  • P/B Ratio
  • 2.6
  • Average True Range
  • 3.42
  • EPS
  • 0.57
  • Dividend Yield
  • 0
  • MACD Signal
  • -3.24
  • RSI
  • 38.21
  • MFI
  • 41.31

Lyka Labs Financials

Lyka Labs Technicals

EMA & SMA

Current Price
₹75.06
-1.37 (-1.79%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹78.24
  • 50 Day
  • ₹84.27
  • 100 Day
  • ₹91.67
  • 200 Day
  • ₹101.74

Resistance and Support

75.75 Pivot Speed
  • R3 79.59
  • R2 78.54
  • R1 76.80
  • S1 74.01
  • S2 72.96
  • S3 71.22

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lyka Labs has an operating revenue of Rs. 136.91 Cr. on a trailing 12-month basis. An annual revenue growth of 25% is outstanding, Pre-tax margin of 8% is okay, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 18%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 11 which is a POOR score indicating inconsistency in earnings, a RS Rating of 8 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 52 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lyka Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results & Others To consider other business matters. to conisder 1. To Approve Redemption of unlisted 1,08,570 10% Cumulative Redeemable Preference Shares of Rs.100/- each. 2. Other business matters.
2025-09-29 Others Rs.0.00 to conisder 1. To Approve Redemption of unlisted 1,08,570 10% Cumulative Redeemable Preference Shares of Rs.100/- each. 2. Other business matters.
2025-08-01 Quarterly Results
2025-05-26 Audited Results
2025-02-04 Quarterly Results

Lyka Labs F&O

Lyka Labs Shareholding Pattern

58.16%
0.01%
0.28%
0.17%
0%
31.51%
9.87%

About Lyka Labs

  • NSE Symbol
  • LYKALABS
  • BSE Symbol
  • 500259
  • Managing Director & CEO
  • Mr. Kunal Gandhi
  • ISIN
  • INE933A01014

Similar Stocks to Lyka Labs

Lyka Labs FAQs

Lyka Labs share price is ₹75 As on 25 December, 2025 | 21:26

The Market Cap of Lyka Labs is ₹267.9 Cr As on 25 December, 2025 | 21:26

The P/E ratio of Lyka Labs is 130.4 As on 25 December, 2025 | 21:26

The PB ratio of Lyka Labs is 2.6 As on 25 December, 2025 | 21:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23